Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12489426 | 0.85 | DYRK1A (0.46) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL12489541 | 0.85 | KEAP1 (0.50) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL24032027 | 0.85 | KEAP1 (0.50) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL26644030 | 0.84 | KEAP1 (0.49) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL28563494 | 0.84 | KEAP1 (0.49) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL28563492 | 0.84 | KEAP1 (0.49) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL26644023 | 0.84 | KEAP1 (0.49) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL18885057 | 0.82 | KEAP1 (0.47) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL24032026 | 0.82 | DYRK1A (0.44) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL20991102 | 0.82 | DYRK1A (0.44) | DYRK1AKEAP1MEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | DYRK1A 4212/4885KEAP1 2210/4885MEN1 3127/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | DYRK1A 849/4885KEAP1 283/4885MEN1 2168/4885 |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE2A | DYRK1A 2743/4885KEAP1 2501/4885MEN1 2960/4885 |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | DYRK1A 2471/4885KEAP1 655/4885MEN1 2342/4885 |
| US-20090042897-A1 | Chemical Compounds | NPY5R, NPY1R, NPY2R | DYRK1A 272/4885KEAP1 4283/4885MEN1 989/4885 |
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | DYRK1A 3481/4885KEAP1 4582/4885MEN1 4650/4885 |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | DYRK1A 2214/4885KEAP1 1739/4885MEN1 4092/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | DYRK1A 2190/4885KEAP1 574/4885MEN1 3173/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | DYRK1A 4621/4885KEAP1 806/4885MEN1 3994/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | DYRK1A 4210/4885KEAP1 2215/4885MEN1 3197/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | DYRK1A 4826/4885KEAP1 417/4885MEN1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.